Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Sibel Blau, MD, on the improvement of care via AI, especially in high risk cancer patients

Dr. Blau, Medical Director, Northwest Medical Specialties, on how artificial intelligence is improving cancer care, especially in predicting high risk cancer patients

Tags: Big Data & Cancer CareCOA Conference CoveragePatient Care (includes Supportive Care, Palliative Care, Survivorship, QOL, Advocacy, Adverse Events, Pain Management)Prevention, Risk Factors, Epidemiology, and DisparitiesTechnology (includes EMR, Digital, Devices)

Published: 04 May 2020

Recent Videos: Prevention, Risk Factors, Epidemiology, and Disparities

video

Sibel Blau, MD, on the improvement of care via AI, especially in high risk cancer patients

Dr. Blau, Medical Director, Northwest Medical Specialties, on how artificial intelligence is improving cancer care, especially in predicting high risk ...

video

Jeffrey Patton, MD, recalls barriers to overcome when treating patients with cancer during the COVID-19 pandemic

Dr. Patton, CEO, Tennessee Oncology, recalls big barriers to overcome when treating patients with cancer during the COVID-19 pandemic

Related Videos

video-image

Jeffrey Patton, MD, recalls barriers to overcome when treating patients with cancer during the COVID-19 pandemic

video-image

More money should be allocated to early detection and screening in colorectal cancer ASCO GI 2016

video-image

Does the Asian population differ from the western populations in regards to gastric cancers

video-image

Derek Raghavan, MD, examines the projected cost of new GNRH antagonist therapy and its implications

video-image

Derek Raghavan, MD, discusses Mobile screening Chest CT project for use in underserved populations

video-image

Marcia Brose, MD, PhD, provides opinion on who should be tested TRK fusions

video-image

Marcia Brose, MD, PhD, expounds on what should be done for patients who progress on larotrectinib

video-image

Marcia Brose, MD, PhD, on biopsy requirements for optimal evaluation for actionable TRK fusions

video-image

Marcia Brose, MD, PhD, describes how testing for TRK abnormalities are accomplished

video-image

Marcia Brose, MD, PhD, discusses the dosing, safety and efficacy of larotrectinib reported at ASCO20

video-image

Marcia Brose, MD, PhD, provides an overview of TRK fusion treatment in cancer patients

video-image

Andres Poveda, MD, provides perspective on the digital format of ASCO20

video-image

Daneng Li, MD, on the study results investigating the geriatric assessment tool & chemo side effects

video-image

Daneng Li, MD, describes the geriatric assessment tool developed at City of Hope

video-image

Bruce Feinberg DO, explains strategies that are or should be provided for managing cancer survivors

video-image

Bruce Feinberg, DO, provides examples of social determinants of health and how they qualify as this

video-image

Bruce Feinberg, DO, discusses the importance of social determinants to the health of cancer patients' outcomes

video-image

Sankalp Sethi & Jeffrey Patton, MD, on how pharma can help community oncology’s COVID-19 challenges

video-image

Sankalp Sethi and Jeffrey Vacirca, MD, FACP, examine partnering with pharma during COVID-19

video-image

Bruce Feinberg, DO, on the understanding medical oncologists have on social determinants of health

video-image

Dinesh Kapur, MD, explains why his practice eventually decided to join OneOncology

video-image

Dinesh Kapur, MD, describes how OneOncology welcomed his group and impressive treatment resources

video-image

Dinesh Kapur, MD, provides thoughts on early impressions of CMMI and the Oncology Care First model

video-image

Dinesh Kapur, MD, shares thoughts on OCM reducing the cost of care and status of the quality

video-image

Robert J. Brooks, MD, offers advantages and disadvantages of joining a large oncology group

video-image

Robert J. Brooks, MD, advises oncology practices that are considering whether to stay independent or to join a larger group of oncologists

video-image

Robert J. Brooks, MD, describes how OneOncology has welcomed his group and impressive resources that help treat cancer patients

video-image

Stephen M. Schleicher, MD, provides examples of how aligning incentives has improved the quality of cancer care delivery while reducing the overall cost of care

video-image

Stephen M. Schleicher, MD, MBA, describes how the cost of drugs are impacting the effectiveness of APMs

video-image

Sibel Blau, MD, shares examples of applied informatics being incorporated into patient management

video-image

Sibel Blau, MD, expounds upon maintaining quality care with non-clinical staff working remotely

video-image

Kathy Oubre, describes robotic process automation and how it is helping with prior authorization

video-image

Kathy Oubre, details how creating tailored patient education has enhanced patient/provider relationships

video-image

Kathy Oubre, considers the predicted surge in cancer patients after the COVID-19 pandemic

video-image

Kathy Oubre, offers best practices and new programs being implemented to safely treat patients during the COVID-19 pandemic

video-image

Debra Patt, MD, on how applied informatics is being incorporated into cancer patient management

video-image

Debra Patt MD, expounds on the improvement of cancer care via artificial intelligence

video-image

Debra Patt, MD, offers opinion on whether embracing informatics is worth the financial investment

video-image

Jeffrey Patton, MD, expounds upon maintaining quality care with non-clinical staff working remotely

video-image

Jeffrey Patton, MD, anticipates whether smaller practices will be able to survive the pandemic or if they are in danger of closing due to lack of resources

video-image

Jeffrey Patton, MD, describes his care team's strengths during this pandemic and habits to continue post pandemic

video-image

Jeffrey Patton, MD, provides thoughts regarding the future of cancer care amidst a national crisis and providing quality cancer care across the country

video-image

Steven D'Amato, RPH, BSPharm, on the adoption of telemedicine and its impact on the patient/provider relationship

video-image

Steven D'Amato, RPH, BSPharm, describes best practices and new programs being adopted to treat patients during the COVID-19 pandemic

video-image

Steven D'Amato, RPH, BSPharm, on his team's strength as a result of the pandemic and habits to continue

video-image

Alti Rahman, MHA, MBA, on how robotic process automation aids with prior authorizations in his practice

video-image

Alti Rahman, MHA, MBA, offers an assessment of prior authorizations during the COVID-19 pandemic

video-image

Alti Rahman, MHA, MBA, explains the adoption of telemedicine and reimbursement expectations

video-image

Nick Recker, on the effectiveness of interoperability between telehealth platforms and oncology EMRs

video-image

Nick Recker, explains how successful oncology practices integrate telehealth beyond the COVID-19 pandemic

video-image

Nick Recker, shares issues facing practices as they rush to integrate telehealth into practice operations

video-image

Nick Recker, describes the role telehealth has played for healthcare providers during this current COVID-19 pandemic

video-image

Bo Gamble, describes the most common mistakes that practices make when coding for oncology treatment

video-image

Bo Gamble, expands on the practice coding problem and repercussions of improper coding

video-image

Bo Gamble, recommends best practices regarding proper coding for oncology practices

video-image

Bo Gamble, illustrates how practices are dealing with adding new CMS telehealth/telemedicine in the midst of the COVID-19 pandemic

video-image

Bo Gamble, shares concerns on the coding changes coming in 2021 and the impact impact they may have on community oncology

video-image

Antonio Ciaccia, expresses advantages Pharmacy Benefit Managers may bring to the healthcare system

video-image

Antonio Ciaccia, demonstrates how Pharmacy Benefit Managers are gaming the healthcare system

video-image

Antonio Ciaccia, explains how smaller pharmacies compete with PBMs and how they are being priced out

video-image

Antonio Ciaccia, on changes that need to be made on a national level that would bring Pharmacy Benefit Managers (PBMs) more in line with the interests of cancer patients and payers

video-image

Martin Dietrich, MD, PhD, provides thoughts on how socioeconomic factors affect on access to Comprehensive Genomic Profiling (CGP) tests and subsequent decision making

video-image

Martin Dietrich MD, PhD, offers resources to aid decision making after receiving Comprehensive Genomic Profiling tests results

video-image

Martin Dietrich, MD, shares concerns about the validity of Comprehensive Genomic Profiling tests and patient decision making

video-image

Martin Dietrich, MD, PhD, explains ordering Genomic Profiling (CPG) tests in the community oncology setting and the timeline of test results

video-image

Martin Dietrich, MD, PhD, describes a Comprehensive Genomic Profiling test, when it should be ordered, and information the test results provides

video-image

Kashyap Patel, MD, recalls his practice's adaption to OCM 1.0 and further adaption to OCM 2.0

video-image

Kashyap Patel, MD, updates us on the stance of OCM 2.0 as of the annual COA meeting 2020

video-image

Kashyap Patel, MD, provides examples of how aligning incentives has improved the quality of cancer care delivery while reducing the overall cost of care

video-image

Kashyap Patel, MD, expresses early impressions of CMMI and the Oncology Care First (OCF) model

video-image

Thomas Sonderberg, expresses opinion on components of care that are essential for employers to consider as part of their comprehensive coverage of their employees

video-image

Thomas Sonderberg, on the needs of small to midsize employers compared to larger employers with more contract leverage

video-image

Thomas Sonderberg, provides concerns of an employer coverage of cancer care and also the good news in cancer care

video-image

Thomas Sonderberg, describes the scope of cancer care cost to an employer and variations in coverage by types of employer

video-image

Kathy Oubre, on cancer patients being given home infusions of treatments during the COVID-19 pandemic

video-image

Stephen M. Schleicher, MD, MBA, on early impressions of CMMI and the Oncology Care First (OCF) model

video-image

Dinesh Kapur, MD, expresses changes in Eastern Connecticut Hematology Oncology amidst the COVID-19 pandemic

video-image

Sibel Blau, MD, describes her care team's strength while embracing new communications and technology in the midst of the COVID-19 pandemic

video-image

Steven D'Amato, RPh, BScPharm, on maintaining quality of care with non-clinical staff working remotely and the steps being taken to support this situation

video-image

Jeffrey Patton, MD, elaborates on critical success factors for providing quality cancer care during the COVID-19 pandemic

video-image

Debra Patt, MD, on how informatics work with physicians to aid in treatment decision making at the point of care

video-image

Thomas Sonderberg, describes challenges that employers face managing cancer care costs and the price of drugs

video-image

Bo Gamble, expounds on new services and associated codes that are important in the era of payment reform

video-image

Alti Rahman, MHA, MBA, shares examples of new practices being implemented to safely treat cancer patients through the COVID-19 pandemic

video-image

Nick Recker, comments on security issues related to rapid adoption of Telehealth in oncology practices

video-image

Antonio Ciaccia, describes pitfalls oncology practices need to know when prescribing a specialty cancer drug at a Pharmacy Benefit Managers-owned pharmacy

video-image

Martin Dietrich, MD, PhD, provides examples of how genetic profile tests are being used to make decisions on patient care

video-image

Kashyap Patel, MD, describes whether quality of care has suffered or improved as OCM reduces the cost of cancer care

video-image

Jeff Vacirca, MD, discusses the capabilities of OneOncology's IT system

video-image

Dan Wygal on how benefit design & value based contracting may make cancer drugs more affordable

video-image

Jeff Vacirca, MD, explains the synergy between three cancer centers that make up OneOncology

video-image

Dan Wygal explains what AstraZeneca is doing to help make cancer drugs more accessible for patients

video-image

Jeff Vacirca, MD, explains why OneOncology is a unique practice model

video-image

Dan Wygal provides perspective on value-based contracting in oncology

video-image

Jeff Vacirca, MD, regarding the novel practice models presented at COA 2019

video-image

Jax Zummo outlines some of the concerns with value-based contracting

video-image

Jax Zummo explains how value-based contracting works

video-image

Jax Zummo provides opinion on how the pharmaceutical industry is helping community oncology

video-image

Lee Schwartzberg, MD, explains the key drivers of success for OneOncology

video-image

Michael Schuh, BS, PharmD, MBA, discusses the latest advances in integrative medicine

video-image

Robin Shah considers how OneOncology is poised for growth

video-image

Lee Schwartzberg, MD, shares his goals as medical director of OneOncology

video-image

Michael Schuh, BS, PharmD, MBA, regarding supplements and integrative medicine in cancer care

video-image

Jax Zummo provides perspective on the rising cost of cancer drugs and patient access

video-image

Robin Shah regarding the capabilities of OneAnalytics

video-image

Lee Schwartzberg, MD, on how step therapy & utilization management are impacting community oncology

video-image

Michael Schuh, BS, PharmD, MBA, elaborates on integrative medicine

video-image

Jeff Patton, MD, considers whether OneOncology is open to growth in new markets

video-image

Kashyap Patel, MD, tells us how tele-medicine is changing the way cancer treatment is delivered

video-image

Christine Pfaff, RPh, explains how medically-integrated pharmacies improve cancer care

video-image

Jeff Patton, MD, shares details regarding OneOncology's advanced IT platform

video-image

Debra Patt, MD, evaluates the aggregation trends in community oncology

video-image

Kashyap Patel, MD, regarding two-sided risk and participation in the OCM

video-image

Christine Pfaff, RPh, discusses the challenges associated with medically-integrated pharmacies

video-image

Jeff Patton, MD, regarding key drivers of success for OneOncology

video-image

Debra Patt, MD, on why it is important for community oncologists to partner with associations

video-image

Kashyap Patel, MD, explains how practices can leverage data to negotiate stronger payer contracts

video-image

Christine Pfaff, RPh, explains why cancer centers should embrace medically-integrated pharmacies

video-image

Jeff Patton, MD, on why community oncologists should embrace novel practice models

video-image

Debra Patt, MD, regarding important policy updates coming out of COA 2019

video-image

Kashyap Patel, MD, offers opinion on novel practice models

video-image

Christine Pfaff, RPh, on how COPA is helping community oncology manage their dispensing pharmacies

video-image

Jeff Patton, MD, considers some of the important challenges & solutions for community oncology

video-image

Debra Patt, MD, shares some of the important takeaways from the 2019 COA Conference

video-image

Kashyap Patel, MD, discusses keys to success for today's oncology practices

video-image

Sonia Oskouei, PharmD, DPLA, elaborates on the reimbursement challenges facing biosimilars

video-image

Sonia Oskouei, PharmD, DPLA, speculates on the future of biosimilars

video-image

Ted Okon reflects on past victories for COA and speculates on future progress

video-image

Sonia Oskouei, PharmD, DPLA, on the clinical challenges associated with the adoption of biosimilars

video-image

Ted Okon on what community oncologists should know about the recent PBM hearings

video-image

Sonia Oskouei, PharmD, DPLA, on the differences between approval for biologics & biosimilars

video-image

Ted Okon on the scope of the step therapy & utilization management concern for community oncologists

video-image

Jonathan Levitt explains how DIR fees are impacting community oncology

video-image

Ted Okon on whether there is a disconnect between policy & the realities of community oncology

video-image

Jonathan Levitt considers how state legislation regarding community oncology has changed

video-image

John Frownfelter, MD, FACP, on how AI is bringing about a better understanding of the cancer patient

video-image

Jonathan Levitt on what has happened in the last 6 months with PBMs & state Medicaids

video-image

John Frownfelter, MD, FACP, outlines some of the hurdles AI has introduced into clinical practice

video-image

Ben Jones considers recent policy changes of which oncologists should be aware

video-image

John Frownfelter, MD, FACP, explains how artificial intelligence is contributing to value-based care

video-image

Ben Jones offers his opinion on priority policy concerns

video-image

John Frownfelter, MD, FACP, explains how artificial intelligence is being applied to cancer care

video-image

Nicolas Ferreyros, on the influence of pharmacy benefit managers

video-image

Ira Klein, MD, MBA, FACP, on embracing value-based oncology care

video-image

Nicolas Ferreyros, on what oncologists should know about their federal policymakers

video-image

Ira Klein, MD, MBA, FACP, provides perspective on the rising cost of cancer drugs

video-image

Nicolas Ferreyros, explains why oncologists should communicate with their local representatives

video-image

Ira Klein, MD, MBA, FACP, on the role of value in cancer drug development

video-image

Melissa Johnson, MD, shares her thoughts on biomarker development in NSCLC

video-image

Melissa Johnson, MD, speculates on exciting developments in the treatment of NSCLC

video-image

Anshu Jain, MD, tells us what physicians & payers should know about proton therapy

video-image

Melissa Johnson, MD, on the updated NCCN guidelines in regards to PD-L1 testing

video-image

Anshu Jain, MD, on the current controversy regarding proton therapy in cancer care

video-image

Melissa Johnson, MD, considers the recent data investigating atezolizumab in SCLC

video-image

Anshu Jain, MD, explains why proton therapy is important in terms of delivery & outcomes

video-image

Robert E. Baird, Jr., RN, MSA, CASC, shares how COA is supporting Dayton Physicians Network

video-image

Matthew Hall, MD, tells us what physicians & payers should know about proton therapy

video-image

Robert E. Baird, Jr., RN, MSA, CASC, shares key takeaways from the 2019 COA Annual Conference

video-image

Matthew Hall, MD, considers whether the application of proton therapy is growing

video-image

Lakshmi Aggarwal, MD, explains why transparency is necessary in the healthcare system

video-image

Matthew Hall, MD, on the difference between photon therapy & proton therapy

video-image

Lakshmi Aggarwal, MD, considers the role of politics in oncology

video-image

Lucio Gordan, MD, shares how the shift in site of care is impacting community oncology

video-image

Lakshmi Aggarwal, MD, offers opinion on the evolving landscape of oncology

video-image

Lucio Gordan, MD, explains how practices should leverage their OCM performance data

video-image

Jesse Dresser evaluates the impact of payer trends on drug manufacturers' market access strategy

video-image

Lucio Gordan, MD, on best practices in delivering value-based care

video-image

Jesse Dresser shares what legal tools are available to dispensing oncology practices & pharmacies

video-image

Lucio Gordan, MD, describes the primary drivers of the cost of cancer care

video-image

Jesse Dresser considers the challenges for dispensing oncology practices regarding payer networks

video-image

Kathy Gaughran explains how Healthcare Success is helping community oncologists

video-image

Jesse Dresser on the trends he is observing between payers and dispensing practices & pharmacies

video-image

Bobbi Buell, MBA, regarding the biggest changes & challenges in oncology reimbursement in 2019

video-image

Sibel Blau, MD, on the pros & cons associated with participation in a clinically integrated network

video-image

Sean Brusky explains how the pharmaceutical industry is working to help community oncology

video-image

Sibel Blau, MD, elaborates on clinically integrated networks

video-image

Sean Brusky provides Genentech’s perspective on the rising cost of cancer drugs and patient access

video-image

Sibel Blau, MD, tells us more about IQ Oncology

video-image

Sean Brusky on taking value into consideration when developing cancer drugs

video-image

Sibel Blau, MD, shares what the QCCAN is doing for participating members

video-image

Michael Diaz, MD, on how community oncology is shaping the future of cancer care

video-image

Michael Diaz, MD, regarding high priority policy initiatives for COA

video-image

Michael Diaz, MD, articulates his goals for the coming year as president of COA

video-image

Michael Diaz, MD, shares exciting updates from the 2019 Community Oncology Conference

video-image

Stephen Schleicher, MD, MBA, regarding participation in a two-sided risk model

video-image

Stephen Schleicher, MD, MBA, discusses participation in the Oncology Care Model

video-image

Stephen Schleicher, MD, MBA, on the challenges associated with value-based care

video-image

Lisa Rometty on the collaboration between Watson and the VA Precision Oncology Program

video-image

Lisa Rometty shares some of the recent accomplishments of IBM's Watson

video-image

Lisa Rometty elaborates on Watson's role in clinical trial matching

video-image

Lisa Rometty regarding the impact of Watson on real-world evidence and clinical decision making

video-image

Lisa Rometty explains how augmented intelligence is helping oncologists better treat cancer patients

video-image

James Hamrick, MD, on how practicing oncologists and the FDA could utilize real world evidence

video-image

James Hamrick, MD, explains how real world evidence figures into clinical trial design

video-image

James Hamrick, MD, discusses the value of real world evidence data

video-image

Ricky Newton shares what COA & COPA are doing to help practices treat at the point of care

video-image

Ricky Newton on how COA has helped practices keep their in-office dispensing in network

video-image

Ricky Newton discusses how PBMs are impacting in-office dispensing for oncology practices

video-image

Ted Okon, MBA, considers what can be done to encourage PBM transparency

video-image

Ted Okon, MBA, on what COA is doing to help community oncology practices

video-image

Ted Okon, MBA, regarding the key issues faced by community oncologists today

video-image

Ted Okon, MBA, offers his interpretation of the Practice Impact Report released at COA 2018

video-image

Ted Okon, MBA, speculates on the path forward regarding 340B policy

video-image

Ted Okon, MBA, on the impact of the reduction in reimbursement for hospitals participating in 340B

video-image

Robert Rifkin, MD, tells us about biosimilar pricing and reimbursement

video-image

Robert Rifkin, MD, lists those biosimilars now approved or close to approval

video-image

Robert Rifkin, MD, on the hurdles that might prevent adoption of biosimilars by oncologists

video-image

Robert Rifkin, MD, on the impact of extrapolation and interchangeability on biosimilar use

video-image

Robert Rifkin, MD, tells us about the regulatory pathway for gaining FDA approval of a biosimilar

video-image

Robert Rifkin, MD, explains the key features of biosimilars

video-image

Rebecca A. Kirch, JD, explains how CMS & commercial insurers have embraced palliative care

video-image

Rebecca A. Kirch, JD, on factors that should be considered before starting a palliative care program

video-image

Rebecca A. Kirch, JD, discusses the impact of high quality palliative care programs

video-image

Ray Page, DO, PhD, on what oncology practices should be doing to advocate for their patients

video-image

Ray Page, DO, PhD, explains cancer patient advocacy & how it enhances the delivery of cancer care

video-image

Nate Brown offers opinion on whether practices in a MIPS track should consider moving to an APM

video-image

Nate Brown speculates on the future of MIPS and oncology practices

video-image

Nate Brown regarding the steps a practice should take to get started on MIPS

video-image

Nate Brown explains why a practice should participate in MIPS

video-image

Miriam Atkins, MD, elaborates on what cancer patients can do to advocate for themselves

video-image

Miriam Atkins, MD, considers what COA is doing to educate patients on their cancer care

video-image

Michael Kolodziej, MD, FACP, on the legislative issues most salient to community oncologists today

video-image

Michael Kolodziej, MD, FACP, considers how the move from volume to value impacts community oncology

video-image

Mark Fendrick, MD, on cost containment strategies that work best in value-based insurance design

video-image

Mark Fendrick, MD, on designing incentives when dealing with expensive cancer therapies

video-image

Mark Fendrick, MD, considers the challenges associated with value-based insurance design

video-image

Mark Fendrick, MD, provides examples of value-based insurance design in oncology care

video-image

Mark Fendrick, MD, explains the motivation behind value-based insurance design

video-image

Michael Diaz, MD, considers what PBMs can do to help community oncology

video-image

Michael Diaz, MD, discusses what cancer patients can do to advocate for themselves

video-image

Michael Diaz, MD, shares what COA is doing to educate cancer care patients

video-image

Michael Diaz, MD, tells us about the goals of the patient initiative on Capital Hill at COA 2018

video-image

Kathy Oubre on how lobbying has helped influence the community oncology agenda

video-image

Kathy Oubre outlines some of the lobbying tactics that community oncology practices should adopt

video-image

Kathy Oubre explains why it’s important for community oncology practices to participate in lobbying

video-image

Jonathan E. Levitt, Esq. explains why oncology practices should be aware of co-pay aggregators

video-image

Jonathan E. Levitt, Esq. on the importance of PBM transparency

video-image

Jonathan E. Levitt, Esq. discusses the problems that exist between PBMs and oncology providers

video-image

Jonathan E. Levitt, Esq. provides an update on the oncology landscape from a legal perspective

video-image

Jeff Mortier explains what can be done to encourage PBM transparency

video-image

Jeff Mortier speculates on the future of 340B policy

video-image

Jeff Mortier considers how 340B is impacting community oncology

video-image

Jeff Mortier discusses some of the issues presented at Hill Day during COA 2018

video-image

Fred Schnell, MD, compares OCM 2.0 and OCM 1.0

video-image

Fred Schnell, MD, explains what COA is doing to help practices succeed in the OCM

video-image

Fred Schnell, MD, considers why practice transformation is often difficult in oncology

video-image

Debra Patt, MD, MPH, MBA, regarding advances in next-generation sequencing

video-image

Debra Patt, MD, MPH, MBA, considers reimbursement & coverage of CAR-T therapies

video-image

Debra Patt, MD, MPH, MBA, on what community oncologists should know before prescribing CAR-Ts

video-image

Debra Patt, MD, MPH, MBA, explains the benefits & challenges associated with prescribing CAR-Ts

video-image

Debra Patt, MD, MPH, MBA, analyzes the logistics associated with CAR-T therapies

video-image

Debra Patt, MD, MPH, MBA, on CMS’s National Coverage Determination & next-generation sequencing

video-image

Debra Patt, MD, MPH, MBA, regarding the reliability of next-generation sequencing

video-image

Debra Patt, MD, MPH, MBA, on the progress being made in next-generation sequencing

video-image

Bud Pierce, MD, describes how Oregon Oncology Specialists has evolved

video-image

Bud Pierce, MD, explains what his practice is doing to alleviate financial toxicity

video-image

Bud Pierce, MD, regarding the doctor-patient relationship in today’s oncology landscape

video-image

Brian DeLashmutt considers cost of care in hospital-based & community oncology settings

video-image

Brian DeLashmutt shares details of his own cancer care experience

video-image

Houston Holmes, MD, MBA, FACP, provides perspective on reimbursement & coverage of CAR-T therapies

video-image

Houston Holmes, MD, MBA, FACP, on what community oncologists should know about prescribing CAR-Ts

video-image

Houston Holmes, MD, MBA, FACP, regarding the benefits & challenges of prescribing CAR-T therapies

video-image

Houston Holmes, MD, MBA, FACP, on the logistics associated with CAR-T therapies

video-image

Suanne Gersdorf, FACHE, MSB, on the impact of value-based care and easing financial toxicity

video-image

Suanne Gersdorf, FACHE, MSB, shares how 340B has impacted her practice

video-image

Suanne Gersdorf, FACHE, MSB, considers how EHR data can be used to improve outcomes

video-image

Suanne Gersdorf, FACHE, MSB, on how oncology practices have become more efficient in utilizing APNs

video-image

Suanne Gersdorf, FACHE, MSB, regarding the importance of embracing APNs

video-image

Harry “Mac” Barnes, MD, explains the benefits of training advanced practitioners

video-image

Harry “Mac” Barnes, MD, elaborates on the role of advanced care providers in cancer patient care

video-image

Melissa Johnson, MD, on how Next Generation Sequencing is relevant to the treatment of NSCLC

video-image

Melissa Johnson, MD, discusses combinations and the treatment of lung cancer

video-image

Melissa Johnson, MD, on lung cancer patients that have a PD-L1 expression that is less than 1%

video-image

Melissa Johnson, MD, on stratifying newly diagnosed lung cancer patients with the PD-L1 biomarker

video-image

Melissa Johnson, MD, clarifies how physicians should use the PD-L1 biomarker

video-image

Michael Seiden, MD, PhD, tells us how big data is helping to advanced clinical progress

video-image

Git Patel explains how technology can help practices acquire more revenue

video-image

Bobby Green, MD, analyzes the role of health technology companies in the design of APMs

video-image

Bobby Green, MD, shares how big data can make a positive contribution to payment reform

video-image

Bobby Green, MD, regarding big data and clinical progress

video-image

Ann Marie Edwards tells us how technology has impacted the delivery of value-based care

video-image

Jamie Bachman, MPA, elaborates on the issue of compatibility and oncology-specific EHRs

video-image

Jamie Bachman, MPA, on how integrating various software into EHRs improves processes

video-image

Jamie Bachman, MPA, regarding important features that every oncologist should have in their EHR

video-image

Jamie Bachman, MPA, on the potential drawbacks associated with oncology-specific EHRs

video-image

Jamie Bachman, MPA, offers examples of how EHRs are allowing practices to improve processes

video-image

Jamie Bachman, MPA, considers whether EHRs are making practices more efficient

video-image

Charles Loprinzi, MD, on the importance of physician communication in making an end of life plan

video-image

Charles Loprinzi, MD, considers the best approach to preventing nausea during chemotherapy

video-image

Charles Loprinzi, MD, discusses managing nasal vestibulitis during cancer treatment

video-image

Charles Loprinzi, MD, explains the role of palliative and supportive care in medical oncology

video-image

Erin Stevens, MD, on how treating sexual dysfunction fits into a symptom management plan

video-image

Erin Stevens, MD, elaborates on interventions to address sexual dysfunction in cancer patients

video-image

Erin Stevens, MD, on why oncologists should be concerned about sexual health in their patients

video-image

Erin Stevens, MD, considers the prevalence of sexual dysfunction in advanced cancer patients

video-image

Sandip Patel, MD, discusses some solutions for managing toxicities associated with immunotherapies

video-image

Sandip Patel, MD, considers immunotherapy combinations and the likelihood of severe adverse events

video-image

Sandip Patel, MD, on identifying patient types likely to experience immune-related adverse events

video-image

Sandip Patel, MD, describes the prominent safety challenges with administration of immunotherapies

video-image

Sandip Patel, MD, on the role of immunotherapies when treating cancer near end of life

video-image

Sharon Bober, PhD, describes how treating sexual dysfunction fits into a symptom management plan

video-image

Sharon Bober, PhD, considers intervention methods to address sexual dysfunction in cancer patients

video-image

Sharon Bober, PhD, explains how sexual health fits into quality of life in patient-reported outcomes

video-image

Sharon Bober, PhD, elaborates on the prevalence of sexual dysfunction in advanced cancer patients

video-image

Timothy Morgenthaler, MD, on what drugs seem to be most effective when treating insomnia

video-image

Timothy Morgenthaler, MD, discusses prevention of insomnia in susceptible advanced cancer patients

video-image

Timothy Morgenthaler, MD, regarding the prevalence of insomnia when treating advanced cancer

video-image

Jeannie Brant, PhD, APRN, AOCN, FAAN, on the role of a medical home and palliative care

video-image

Jeannie Brant, PhD, APRN, AOCN, FAAN, on how palliative care looks in a rural practice setting

video-image

Jeannie Brant, PhD, APRN, AOCN, FAAN, on innovations that support the integration of palliative care

video-image

Jeannie Brant, PhD, APRN, AOCN, FAAN, discusses integrating palliative care in cancer centers

video-image

Jeannie Brant, PhD, APRN, AOCN, FAAN, on incorporating palliative care at Billings Cancer Center

video-image

Rudolph Navari, MD, considers how treating nausea fits into a broader symptom management plan

video-image

Rudolph Navari, MD, regarding effective drugs or drug regimens when treating CINV in advanced cancer

video-image

Rudolph Navari, MD, on identifying advanced cancer patients more likely to experience severe nausea

video-image

Rudolph Navari, MD, describes the prevalence of nausea when treating advanced cancer

video-image

Thaddeus Beck, MD, FACP, on how Watson for Clinical Trials Matching can increase practice efficiency

video-image

Thaddeus Beck, MD, FACP, explains how Watson for Clinical Trials Matching operates

video-image

Thaddeus Beck, MD, FACP, shares his experience working with Watson for Clinical Trials Matching

video-image

Daniel Petrylak, MD, offers recommendations for bladder cancer patients

video-image

Andrew Pecora, MD, FACP, CPE, shares how COTA and IBM Watson are working together

video-image

Andrew Norden, MD, speculates on the future of Watson for oncology

video-image

Andrew Norden, MD, on how physicians can take advantage of Watson’s expanding library of tumor types

video-image

Andrew Norden, MD, describes the clinical utility of Watson for oncology

video-image

Andrew Norden, MD, on how Watson for Clinical Trial Matching (CTM) operates

video-image

Skip Burris, MD, offers his opinion on liquid biopsies as the new standard of care

video-image

Lucio Gordan, MD, shares his concerns with PBMs as they affect community oncology practices

video-image

Ray Bailey on novel adherence approaches to help patients stay on oral cancer agents

video-image

Ray Bailey explains how he works with payers to dispense oral cancer agents to patients

video-image

David Eagle, MD, shares how his small practice is successful in today’s oncology environment

video-image

David Eagle, MD, compares the rate of oncology spending to rate of total healthcare spending

video-image

David Eagle, MD, evaluates what part of total oncology care spending is drug spending

video-image

Joseph Lynch, MD, on Professional Services Agreements versus full employment with a hospital system

video-image

Joseph Lynch, MD, evaluates how patients react to the hospital setting versus community setting

video-image

Joseph Lynch, MD, shares how moving to the hospital setting influences quality of care

video-image

Joseph Lynch, MD, on how community oncologists can work closer with their local hospital system

video-image

Joseph Lynch, MD, describes his practice's current arrangement with St. Francis Health System

video-image

Joseph Lynch, MD, on why independent community oncology practices join hospital systems

video-image

Bobby Green, MD, describes how oncologists can leverage data to better utilize claims data

video-image

Bobbi Buell offers advice to practices on how to guarantee good coding

video-image

Bobbi Buell on the implications of mistakes in coding

video-image

Patrick Cobb, MD, describes moving to an outpatient setting and the impact on cancer care

video-image

Patrick Cobb, MD, on how clinical trials improve care and contribute a revenue stream

video-image

Skip Burris, MD, shares how clinical pathways impact prescribing decisions

video-image

Skip Burris, MD, discusses the importance of oral oncolytics in today’s market place

video-image

Skip Burris, MD, on the impact of OCM on large community practices

video-image

Bruce Feinberg, DO, describes how Cardinal Health is changing the world of oncology

video-image

Bruce Feinberg, DO, shares his special interest in value-based care

video-image

Bruce Feinberg, DO, comments on site of care and its impact on cancer economics

video-image

Bruce Feinberg, DO, on what community oncologists should consider with MACRA, MIP’s and OCM

video-image

Jeff Patton, MD, shares how clinical pathways help with value-based efforts

video-image

Jeff Patton, MD, describes the relationship between oral cancer agents and practice economics

video-image

Jeff Patton, MD, on whether the Oncology Care Model impacts the prescribing of oral cancer agents

video-image

Jeff Patton, MD, reflects on how his practice manages the transition to value-based care

video-image

Jeff Patton, MD, explains how Tennessee Oncology has transformed to participate in OCM

video-image

Lucio Gordan, MD, considers how 340B is impacting physicians and practices

video-image

Robert Baird Jr. on forging beneficial relationships with other cancer stakeholders

video-image

Robert Baird Jr. reflects on how his practice has changed as a result of OCM

video-image

Edward Li on how clinical pathways are making progress towards their original goals

video-image

Edward Li reflects on how pathways have impacted oncology treatment over the last 5 years

video-image

Edward Li considers how comfortable medical oncologists and patients should be with biosimilars

video-image

Edward Li provides examples of oncology targeting biosimilars that are nearing approval

video-image

Edward Li outlines the legal challenges surrounding biosimilars and market entry

video-image

Edward Li on the status of the biosimilars regulatory pathway

video-image

Ted Okon lists key takeaways from the 2017 COA meeting

video-image

Ted Okon describes how PBMs affect oncologists and cancer patients

video-image

Ted Okon shares the latest news on the 340B policy

video-image

Ben Jones gives advice to practices interested in advocating for community oncology

video-image

Ben Jones shares what McKesson Specialty Health is doing to help community oncologists thrive

video-image

Ben Jones on the hot policy topics impacting the delivery of quality cancer care

video-image

Lalan Wilfong, MD, shares lessons from his experience participating in OCM

video-image

Lalan Wilfong, MD, explains how OCM has impacted cancer patients in his practice

video-image

Lalan Wilfong, MD, provides opinion on how OCM is changing his practice

video-image

Debra Patt, MD, considers how community oncology contributes to clinical research advancement

video-image

Debra Patt, MD, on technological advances in cancer care and community oncology

video-image

Debra Patt, MD, shares how community oncology has contributed to advances in population health

video-image

Debra Patt, MD, elaborates on how community oncology contributes to the Cancer Moonshot

video-image

Miriam Yvette Jones Atkins, MD, explains how the COA Patient Advocacy Network makes a difference

video-image

Miriam Yvette Jones Atkins, MD, on involving patients in the COA Patient Advocacy Network

video-image

Miriam Yvette Jones Atkins, MD, on how the COA Patient Advocacy Network benefits patients

video-image

Jeff Vacirca, MD, shares how COA is addressing the DIR fees coming from PBMs

video-image

Jeff Vacirca, MD, on COA’s efforts to represent community oncologists

video-image

Jeff Vacirca, MD, discusses DIR fees and how COA hopes to solve the PBM fee problem

video-image

Jeff Vacirca, MD, on how COA is addressing Part B concerns among community oncologists

video-image

James Hamrick, MD, reflects on how the EMR can overcome quality reporting challenges

video-image

James Hamrick, MD, debriefs physicians on how to be more efficient in their workflow

video-image

James Hamrick, MD, on how practices can succeed in value-based care by managing unstructured data

video-image

Lucio Gordan, MD, offers recommendations for practices to improve clinical trial participation

video-image

Lucio Gordan, MD, on how community oncology practices can utilize their own data

video-image

Lucio Gordan, MD, reflects on how he sees community oncology using big data

video-image

Matt Farber elaborates on how specialty pharmacies work with payers to help deliver cancer care

video-image

Matt Farber describes how specialty pharmacies differ

video-image

Matt Farber provides insight on the evolution of specialty pharmacies

video-image

Matt Farber explains the role of specialty pharmacy in delivering quality cancer care

video-image

Skip Burris, MD, offers his opinion on searching for rare mutations

video-image

David Eagle, MD, compares small, community oncology practices with large practices and hospitals

video-image

Ray Bailey on how participation in OCM impacts the in-house pharmacy at FCS

video-image

Bobbi Buell explains how practices can avoid the most common mistakes in billing

video-image

Skip Burris, MD, offers his opinion on molecular profiling patients

video-image

Patrick Cobb, MD, on cancer care costs in hospital outpatient and community settings

video-image

Brad Prechtl offers his opinion on how size influences community oncology practices

video-image

Brad Prechtl explains how “shared savings” works between FCS and a local payer

video-image

Brad Prechtl on the keys to success for Florida Cancer Specialists

video-image

William Harwin, MD, on how clinical pathways impact treatment decisions at FCS

video-image

William Harwin, MD, explains how he manages the quality measures required for OCM

video-image

William Harwin, MD, on working with local payers to deliver quality care

video-image

William Harwin, MD, talks changes at Florida Cancer Specialists since participating in OCM

video-image

William Harwin, MD, describes the shift from fee for service to value-based care

video-image

Barbara McAneny, MD, discusses 1 sided and 2 sided risk associated with participation in the OCM

video-image

Barbara McAneny, MD, shares her concerns with the way OCM is progressing at this point

video-image

Barbara McAneny, MD, on what she would like to accomplish if she became president of the AMA

video-image

Barbara McAneny, MD, discusses how the AMA is helping physicians working in all practice settings

video-image

Ricky Newton provides an example of how a PBM is impacting cancer patient care

video-image

Ricky Newton describes the paper COA is releasing on patient experiences with PBMs

video-image

Ricky Newton tells us how COA is addressing the PBM DIR fees and helping community oncology

video-image

Ricky Newton describes what happened with CVS last year and how COPA is working with CVS today

video-image

Bobby Green, MD, on how oncologists can leverage data to understand real quality care

video-image

Bobby Green, MD, explains how he defines big data

video-image

Barbara McAneny, MD, explains how the AMA and community oncology should interact

video-image

Barbara McAneny, MD, discusses novel payer initiatives she finds interesting

video-image

Robert B. Den, MD, on the QOL differences between clinically localized prostate cancer patients

video-image

Charles Saunders, MD, discusses how value-based care is driving technology innovation in oncology

video-image

Jonathan Hirsch, on precision medicine software helping oncologists make therapeutic decisions

video-image

Steve D’Amato, R.Ph., talks about data capture and data analytics at New England Cancer Specialists

video-image

Steve D’Amato, R.Ph., talks about what technology his practice adopted to participate in OCM

video-image

Steve D’Amato, R.Ph., explains how his practice helps patients get access to cancer care

video-image

James Hamrick, MD, on using real world evidence to learn how to treat cancer patients

video-image

James Hamrick, MD, explains how EMRs help connect patients and caregivers

video-image

Charles Bane, MD, touches on the COME HOME project while discussing the Oncology Care Model

video-image

Charles Bane, MD, touches on the COME HOME project while discussing the Oncology Care Model

video-image

Charles Bane, MD, discusses the practicality of the value tool at Dayton Physicians Network

video-image

Perspective on the NCCN Evidence Blocks by Charles Bane, MD

video-image

Perspective on the ASCO Value Framework by Charles Bane, MD

video-image

Bruce Gould, MD, explains how the value tools could be used in the community practice setting

video-image

Perspective on the NCCN Evidence Blocks provided by Bruce Gould, MD

video-image

Perspective on the ASCO Value Framework provided by Bruce Gould, MD

video-image

Bruce Gould, MD, explains ASCO’s policy toward clinical pathways at this time

video-image

The impact of clinical pathways on quality cancer care as explained by Bruce Gould, MD

video-image

Bruce Gould, MD, describes the concerns his practice has with clinical pathways

video-image

Barbara McAneny, MD, explains why CMS implemented the ASP experiment

video-image

Barbara McAneny, MD, informs as to what practices should know about MACRA

video-image

Barbara McAneny, MD, reviews the COME HOME project’s influence on the Oncology Care Model

video-image

Barbara McAneny, MD, discusses COME HOME’s adaptability to other community oncology practices

video-image

Barbara McAneny, MD, talks about the COME HOME project’s impact on community oncology practices

video-image

Barbara McAneny, MD, discusses the COME HOME project’s future

video-image

Jeff Patton, MD, explains what could happen if the CMS ASP Experiment proceeds as planned by CMS

video-image

Jeff Patton, MD, explains how Tennessee Oncology benefits from being a member of COA

video-image

Jeff Patton, MD, explains why the 2016 COA meeting is a must attend meeting

video-image

Jeff Patton, MD, discusses his new role with the Community Oncology Alliance (COA)

video-image

Deborah Patt, MD, shares her concerns about the CMS ASP Experiment and Part B reimbursement

video-image

Deborah Patt, MD, tells us how chemotherapy costs figure into total care

video-image

Deborah Patt, MD, points out how oncologists can reduce cancer costs

video-image

Deborah Patt, MD, details surprising outcomes from a recent cost study

video-image

Deborah Patt, MD, looks at the bigger expense drivers in cancer care

video-image

David Eagle, MD, gives his opinion on the CMS ASP Experiment

video-image

David Eagle, MD, enumerates what oncologists can do to bring cancer costs down

video-image

David Eagle, MD, lists outcomes from the COA study surprising to oncologists

video-image

David Eagle, MD, details the bigger expenses driving up cancer care costs based on the COA study

video-image

David Eagle, MD, compares costs for treating cancer vs. non-cancer based on the COA study

video-image

David Eagle, MD, talks about COA’s Cost Drivers of Cancer Care study

video-image

Bhuvana Sagar, MD, tells us about the Cigna medical home for oncologists

video-image

Bhuvana Sagar, MD, discusses Cigna’s work with oncologists to find alternative payment models

video-image

Bhuvana Sagar, MD, explains the need for alternative payment models in oncology

video-image

Barry Russo explains the impact of the CMS ASP Experiment

video-image

Practices need to get ready to replace buy and bill explains Barry Russo

video-image

Bruce Gould, MD, explains the characteristics that makes a practice ready for OCM

video-image

Brad Prechtl briefs us on his concerns with the“Medicare Experiment” and its impact

video-image

Brad Prechtl tells how his practice is working to improve cancer care

video-image

Brad Prechtl talks about how community oncology practices can survive today

video-image

Brad Prechtl explains the benefits of community oncology practices joining forces

video-image

Bhuvana Sagar, MD, forecasts the possible Cigna adoption of a Medicare OCM model

video-image

Participation in the Oncology Care Model (OCM) as explained by Barry Russo

video-image

Barry Russo explains how important it is to embrace alternative payment models

video-image

Barry Russo tells us how his practice is getting ready for value-based care

video-image

Patrick Cobb, MD, FACP, looks ahead to treatment innovations that will make a difference

video-image

Patrick Cobb, MD, FACP, talks about some exciting, recent innovations in cancer treatment

video-image

Michael Diaz, MD, talks about working with payers to add quality and value

video-image

Michael Diaz, MD, discusses the challenges in adopting quality and value measures

video-image

Michael Diaz, MD, talks about why the community oncology setting is the best value for patients

video-image

John Fox, MD, predicts if the ASCO Value Framework or NCCN Evidence Blocks will impact drug spend

video-image

John Fox, MD, talks about how Priority might use the ASCO and NCCN value tools

video-image

John Fox, MD, talks about the new value tools from ASCO and NCCN

video-image

John Fox, MD, provides perspective on collaborating with providers on clinical pathways

video-image

A look at cancer clinical pathways with Charles Bane, MD

video-image

Ricky Newton, CPA, updates us on COPA

video-image

Ricky Newton, CPA, details how COPA’s website helps practice managers, pharmacists, and patients

video-image

Ricky Newton, CPA, explains the purpose of COPA’s new In-House and Specialty Pharmacies brief

video-image

Ricky Newton, CPA, tells us what follow up to expect from COPA’s new brief

video-image

Robert Baird fills us in on the Value-Based Purchasing Modifier's impact on Dayton

video-image

Robert Baird details how practices can prepare for the Value-Based Purchasing Modifier and MIPS

video-image

Robert Baird explains how Dayton physicians and payers are collaborating on APMs

video-image

Robert Baird answers questions on Dayton’s participation in the Oncology Care Model

video-image

Skip Burris, MD, outlines the scope of cancer clinical trials at SCRI

video-image

Skip Burris, MD, talks about how CAR-Ts work, and the trials taking place at SCRI

video-image

Skip Burris, MD, looks at the promise of immunotherapies in combination

video-image

Skip Burris, MD, explains goals and outcomes of the My Pathway trial

video-image

Skip Burris, MD, reflects on the promise and concerns with liquid biopsies

video-image

Ted Okon tells us why the CNS ASP Experiment is a bad idea

video-image

Embrace alternative payment models explains Ted Okon

video-image

Todd Murphree, PharmD, tells us how in-house dispensing in his practice benefits patients

video-image

Todd Murphree, PharmD, tells us how in-house dispensing in his practice benefits patients

video-image

Todd Murphree, PharmD, explains the role an in-house pharmacy plays in the quality equation

video-image

Sue Naeyaert predicts whether we will see more cancer biosimilars soon

video-image

Sue Naeyaert tells us what to expect in pricing biosimilars

video-image

A look at the expansion of a biosimilar’s FDA label with Sue Naeyaert

video-image

Sue Naeyaert explains the proposed reimbursement of biosimilars by CMS

video-image

Skip Burris, MD, discusses how precision medicine is changing cancer treatment

video-image

Sue Naeyaert provides her vision of the biosimilar products in development

video-image

Todd Murphree briefs us on ACHC’s oncology accreditation process

video-image

Todd Murphree, PharmD, discusses how ACHC accreditation benefits his practice

video-image

Ted Okon discusses the sessions that stand out at this year's annual meeting

video-image

Ted Okon discusses the 2016 Community Oncology Alliance annual meeting

video-image

Ted Okon discusses the 2016 Community Oncology Alliance annual meeting

video-image

Ted Okon provides an overview of the Cost Drivers in Cancer Care study

video-image

Mary Kruczynski speaks to those who were unable to attend the 2016 Annual COA meeting

video-image

Mary Kruczynski tells us how the 2016 Annual COA meeting benefits health care providers

video-image

Mary Kruczynski reflects on highlights from COA

video-image

Lucio Gordan, MD, lists takeaways from COA that can benefit his own practice

video-image

Lucio Gordan, MD, debriefs providers who didn’t attend on highlights from COA

video-image

Lucio Gordan, MD, reflects on key messages from this year’s COA

video-image

Jeff Vacirca, MD, explains the relevance of the COA/Milliman study to his practice

video-image

Jeff Vacirca, MD, talks about what his community oncology practice is doing to survive

video-image

Jeff Patton, MD, explains how his practice is working to develop alternative payment models

video-image

COA is helping community oncologists by fighting the CMS ASP Experiment by Jeff Patton, MD

video-image

Robert Baird tells us what MIPS are and how practices might use them

video-image

Patrick Cobb, MD, discusses treatment innovations and managing patient’s expectations

video-image

Jeff Vacirca, MD, shares his thoughts on the “Medicare Experiment” on community oncology

video-image

David Eagle, MD, compares treatment costs in different settings

video-image

Mary Kruczynski tells us how the Cost Drivers in Cancer Care study was developed

video-image

Managing patients on regorafenib including adverse events